Singapore markets closed

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
31.81+1.60 (+5.30%)
At close: 04:00PM EDT
31.23 -0.55 (-1.73%)
After hours: 04:05PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.79B
Enterprise value 1.08B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)66.00
Price/book (mrq)2.20
Enterprise value/revenue 40.36
Enterprise value/EBITDA -2.81

Trading information

Stock price history

Beta (5Y monthly) 0.86
52-week change 343.94%
S&P500 52-week change 325.01%
52-week high 335.50
52-week low 319.80
50-day moving average 329.70
200-day moving average 325.50

Share statistics

Avg vol (3-month) 3762.5k
Avg vol (10-day) 3727.08k
Shares outstanding 556.19M
Implied shares outstanding 656.19M
Float 847.6M
% held by insiders 11.62%
% held by institutions 1107.81%
Shares short (28 Mar 2024) 46.6M
Short ratio (28 Mar 2024) 49.54
Short % of float (28 Mar 2024) 411.89%
Short % of shares outstanding (28 Mar 2024) 411.75%
Shares short (prior month 29 Feb 2024) 47.33M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,496.23%

Management effectiveness

Return on assets (ttm)-22.49%
Return on equity (ttm)-36.83%

Income statement

Revenue (ttm)26.82M
Revenue per share (ttm)0.48
Quarterly revenue growth (yoy)64.80%
Gross profit (ttm)N/A
EBITDA -384.86M
Net income avi to common (ttm)-352.09M
Diluted EPS (ttm)-6.33
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)776.93M
Total cash per share (mrq)13.83
Total debt (mrq)72M
Total debt/equity (mrq)8.88%
Current ratio (mrq)12.27
Book value per share (mrq)14.50

Cash flow statement

Operating cash flow (ttm)-296.06M
Levered free cash flow (ttm)-215.06M